To determine the effect of HFD-associated increases in serum HDL and APOA-I levels on the pathological characteristics of AD such as the reactivity of astrocytes and microglia in the hippocampus and hypothalamus, we performed immunofluorescence staining with glial fibrillary acidic protein (GFAP), an astrocyte-specific marker protein, and ionized calcium binding adaptor molecule 1 (Iba1), a microglia-specific marker protein. The gene discussed is GFAP; the disease is Alzheimer disease.